R. McEwen

发表

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

O. Hofmann, J. Barrett, J. Dry, 2016, Nucleic acids research.

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Manish R. Patel, B. Linghu, J. Barrett, 2020, Clinical Cancer Research.

Genes Contributing to Pain Sensitivity in the Normal Population: An Exome Sequencing Study

T. Spector, J. Stephens, S. McMahon, 2012, PLoS genetics.

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Amanda R. Kulick, M. Ladanyi, W. Pao, 2017, Cancer research.

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

N. Shire, N. Rizvi, T. Hembrough, 2020, PloS one.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

B. Taylor, M. Berger, S. Chandarlapaty, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

A. Ravaud, T. Powles, J. Carles, 2021, Nature Medicine.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Yeon-Hee Park, D. Stetson, N. Turner, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

S. Chandarlapaty, J. Baselga, F. Meric-Bernstam, 2021, NPJ breast cancer.

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours

O. Delpuech, J. Dry, M. O’Connor, 2019, Oncotarget.

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

J. Carroll, O. Delpuech, Rasmus Siersbaek, 2018, Molecular Cancer Therapeutics.

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers

N. Camp, S. Barry, O. Delpuech, 2016, Oncotarget.

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

I. Kozarewa, K. Fenwick, G. Schiavon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors

S. Barry, O. Delpuech, Á. Avivar-Valderas, 2017, Clinical Cancer Research.

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer

E. Harrington, Á. Avivar-Valderas, Marcello Maresca, 2018, Oncotarget.

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

O. Delpuech, S. Green, Á. Avivar-Valderas, 2016, Molecular Cancer Therapeutics.

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

O. Delpuech, C. Chresta, S. Guichard, 2015, Molecular Cancer Therapeutics.

Defining actionable mutations for oncology therapeutic development

Jonathan R. Dry, Zhongwu Lai, J. Carl Barrett, 2016, Nature Reviews Cancer.

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

S. Chandarlapaty, J. Baselga, F. Meric-Bernstam, 2021, npj Breast Cancer.

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

B. Taylor, S. Chandarlapaty, J. Baselga, 2020, Clinical Cancer Research.

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

M. Garnett, S. Barry, B. Davies, 2022, Oncogene.

Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).

E. Winer, N. Lin, M. Hughes, 2022, Journal of Clinical Oncology.

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

E. Winer, N. Lin, M. Hughes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients

Justin Guinney, Claus Bendtsen, Charles Ferté, 2013, Clinical Cancer Research.

Serial postoperative ctDNA monitoring of breast cancer recurrence.

Simak Ali, H. Sethi, R. Hastings, 2022, Journal of Clinical Oncology.

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen

U. McDermott, M. Garnett, S. Barry, 2016, Oncotarget.

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

H. L. Wright, R. Moots, T. Spector, 2013 .

Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.

E. Tokunaga, Yeon-Hee Park, D. Cameron, 2023, Journal of Clinical Oncology.

Precompetitive activity to address the biological data needs of drug discovery

Ben Sidders, Christoph Brockel, Lee Harland, 2014, Nature Reviews Drug Discovery.